基于DNA与基于RNA检测肺癌MET外显子14跳跃事件的比较
研究对非小细胞肺癌(NSCLC)肿瘤样本分别采用基于DNA和基于RNA的二代测序检测MET外显子14跳跃。DNA法在856例中检出11例(1.3%),RNA法在404例中检出17例(4.2%),RNA法检出率显著高于DNA法;286例双法检测中RNA法检出10例阳性,其中6例DNA法未检出。DNA法引物结合区基因组缺失可能是假阴性原因,而RNA法高度依赖RNA质量。
要点
- RNA法检出MET外显子14跳跃的比例显著高于DNA法。
- 双法检测的286例中,RNA法检出10例阳性,其中6例DNA法未检出。
- DNA法假阴性可能与引物结合序列的基因组缺失有关。
核心结论
- RNA法通过规避DNA扩增子介导检测的固有局限,检出了更高比例的MET外显子14跳跃病例,但RNA法高度依赖RNA质量,部分临床样本中RNA质量可能欠佳。
研究设计与样本
- 研究对NSCLC患者肿瘤样本分别采用基于DNA的二代测序(扩增子介导靶向富集)和基于RNA的二代测序(锚定多重PCR靶向富集)检测MET外显子14跳跃。
主要发现
- DNA法在856例NSCLC样本中检出11例MET外显子14跳跃变异(1.3%)。
- RNA法在404例样本中检出17例MET外显子14跳跃(4.2%),较DNA法显著增加。
- 286例同时接受两种方法检测的样本中,RNA法检出10例阳性,其中6例DNA法未检出。
- 比较DNA法引物结合位点与已发表的MET外显子14跳跃变异发现,引物结合序列的基因组缺失可能是假阴性的原因。
- 2例DNA法阳性样本因RNA质量差,RNA法结果无法判读。
关键数值与推荐
- DNA法检出率:11/856(1.3%)。
- RNA法检出率:17/404(4.2%),较DNA法显著增加。
- 双法检测样本:286例,RNA法阳性10例,其中6例DNA法未检出。
局限性
- RNA法高度依赖RNA质量,部分临床样本中RNA质量可能欠佳。
- 2例DNA法阳性样本因RNA质量差,RNA法结果无法判读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Genomic variants that lead to MET proto-oncogenem receptor tyrosine kinase (MET) exon 14 skipping represent a potential targetable molecular abnormality in NSCLC. Consequently, reliable molecular diagnostic approaches that detect these variants are vital for patient care. METHODS: We screened tumor samples from patients with NSCLC for MET exon 14 skipping by using two distinct approaches: a DNA-based next-generation sequencing assay that uses an amplicon-mediated target enrichment and an RNA-based next-generation sequencing assay that uses anchored multiplex polymerase chain reaction for target enrichment. RESULTS: The DNA-based approach detected MET exon 14 skipping variants in 11 of 856 NSCLC samples (1.3%). The RNA-based approach detected MET exon 14 skipping in 17 of 404 samples (4.2%), which was a statistically significant increase compared with the DNA-based assay. Among 286 samples tested by both assays, RNA-based testing detected 10 positives, six of which were not detected by the DNA-based assay. Examination of primer binding sites in the DNA-based assay in comparison with published MET exon 14 skipping variants revealed genomic deletion involving primer binding sequences as the likely cause of false negatives. Two samples positive via the DNA-based approach were uninformative via the RNA-based approach due to poor-quality RNA. CONCLUSIONS: By circumventing an inherent limitation of DNA-based amplicon-mediated testing, RNA-based analysis detected a higher proportion of MET exon 14 skipping cases. However, RNA-based analysis was highly reliant on RNA quality, which can be suboptimal in some clinical samples.
引用
- Davies KD, Lomboy A, Lawrence CA, et al. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer. J Thorac Oncol. 2019. PMID: 30639620. doi:10.1016/j.jtho.2018.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。